02.27.2018 Issue 391

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Truven Health Shares Payer Perspectives on OBCs

Friday, Jan. 19, 2018

Truven Health in an opinion brief shared the payer perspective on outcomes-based contracts (OBCs), and offered some insights as to what steps the industry can take to make them “meaningful, sustainable and scalable.”


What’s Gone Awry with Trial Costs?

Express Scripts, Walgreens Boots Partner on Biosimilars

Payers Moving to Tie Precision Medicine, Value

University of Oxford’s HERC Releases Newsletter

Biosimilars: E.U. Payer Perspectives

Abarca, Amgen OK Outcomes-Based Deal for Repatha

States Eye Steps to Reverse Drug Cost Trajectory

Associate Director, Strategic Market Access- CAR-T

Associate Healthcare Outcomes Solutions Director

Market Access / Health Economics Manager, Ireland. €50k-€60k

Health Economics and Market Access (Senior) Consultant, Cambridge, UK

Research Scientist - Outcomes Research/Health Preferences

HEOR and Market Access Researcher

Director, Global Heath Economics and Outcomes Research

Industry Spotlight

Conferences Webinars

National Value-Based Payment and Pay for Performance Summit
    February 28-March 2, San Francisco

11th Annual Oncology Market Access Strategy Summit
    February 28-March 1, San Francisco

Patient Partnering in Clinical Development
    March 6, Berlin

PAP 2018 — 19th Patient Assistance & Access Programs
    March 6-7, Baltimore

Outcomes as a Pathway for Payer-Pharma-Provider Collaboration
    February 28

Online MS Degree in Applied PharmacoEconomics or Managed Care
    March 1

Tailored to Translate: Custom Preclinical Models for Advancing Diverse Therapeutic Strategies in Oncology
    March 14

Common Challenges and Solutions in Analysis and Reporting of PROs in Oncology Clinical Trials
    March 21

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Biosimilars: E.U. Payer Perspectives

MSL Teams: Field Force Size and Structure

Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017

Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) 2017

Market Access Impact: Rheumatoid Arthritis (US) 2017

Reforming Biopharmaceutical Pricing at Home and Abroad

U.S. Presidential Mandate on Value-based Drug Pricing: Moonshot or Wormhole?

The State of Digital Identification and Signatures

Secure Document Workflows in Drug Development

Streamline Regulatory Compliance in Life Sciences with Digital Transaction Management

Special Thanks to Our Partners:
Evidence Partners  Evidera    eyeforpharmaG&J Lee RecruitmentHealthCore
  MAPS    University of FL    IQVIA    TruvenXcenda
OM1ParexelICON Jefferson  Dymaxium
  Curo  PharmeritDRG AbacuseMax Health